Baxter to sell contract manufacturing business for $4.25 billion

10 May 2023
biotech_lab_research_vial_manufacturing_big

In line with  a trend for big life science firms to divest non-core operations, medtech giant Baxter International (NYSE: BAX) is to sell off its biopharma manufacturing unit.

BioPharma Solutions (BPS), a contract development manufacturing organization (CDMO), offers services such as manufacturing and packaging of sterile injectables such as vaccines.

The business will be bought by private equity firm Advent International and growth investor Warburg Pincus, for $4.25 billion in cash.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology